Introduction
The second edition of the EU CAR-T Handbook marks a significant step forward in the evolving field of chimeric antigen receptor T cell (CAR-T) therapy. Building on the success of the first edition, this updated resource reflects the rapid advancements in clinical practice, regulatory frameworks, and scientific innovation. Designed as a comprehensive guide for healthcare professionals, it emphasises the importance of multidisciplinary collaboration, structured patient care pathways, and ongoing education to ensure the safe and effective implementation of CAR-T therapies. With expanded indications, improved safety profiles, and evolving access strategies, this handbook reaffirms the commitment of the EBMT and EHA to advancing cellular therapies and improving outcomes for patients with haematological malignancies.
Watch the Interview
About the editors
Mahmoud Aljurf, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Chiara Bonini, Experimental Haematology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
Vita-Salute San Raffaele University, Milan, Italy
Christian Chabannon, Institut Paoli-Calmettes Comprehensive Cancer Centre and Module Biothérapies du Centre d'Investigations Cliniques de Marseille, INSERM-Aix-Marseille Université-AP-HM-IPC, CBT-1409, Marseille, France
Julio Delgado, Hospital Clínic, FRCB-IDIBAPS, University of Barcelona, Barcelona, Spain
Martin Dreyling, LMU Hospital, Munich, Germany
Jürgen Kuball, UMC Utrecht, Utrecht, The Netherlands
Annalisa Ruggeri, San Raffaele Scientific Institute, Haematology and Bone Marrow Transplantation Unit, Milan, Italy
Marion Subklewe, LMU Hospital, Munich, Germany
Anna Sureda, Institut Català d'Oncologia, Barcelona, Spain
Isabel Sánchez-Ortega, EU CAR-T Handbook Project Lead, EBMT Medical Officer and Education Director